Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Concerning Bacterial Superantigen Vaccines

---
identifier: "/us/fr/02-19708"
source: "fr"
legal_status: "authoritative_unofficial"
title: "Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Concerning Bacterial Superantigen Vaccines"
title_number: 0
title_name: "Federal Register"
section_number: "02-19708"
section_name: "Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Concerning Bacterial Superantigen Vaccines"
positive_law: false
currency: "2002-08-05"
last_updated: "2002-08-05"
format_version: "1.1.0"
generator: "[email protected]"
agency: "Defense Department"
document_number: "02-19708"
document_type: "notice"
publication_date: "2002-08-05"
agencies:
  - "Defense Department"
  - "Army Department"
fr_citation: "67 FR 50650"
fr_volume: 67
fr_action: "Notice."
---


#  Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Concerning Bacterial Superantigen Vaccines

**AGENCY:**

Department of the Army, DoD.

**ACTION:**

Notice.

**SUMMARY:**

In accordance with 37 CFR 404.6 and 404.7, announcement is made of the availability for licensing of U.S. Patent No. 6,399,332 entitled “Bacterial Superantigen Vaccines,” issued June 4, 2002. Foreign rights (PCT/US98/16766) are also available. The United States Government, as represented by the Secretary of the Army has rights in this invention.

**ADDRESSES:**

Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge  Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, Frederick, MD 21702-5012.

**FOR FURTHER INFORMATION CONTACT:**

For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul Mele, Office of Research & Technology Assessment, (301) 619-6664, both at telefax (301) 619-5034.

**SUPPLEMENTARY INFORMATION:**

The present invention relates to genetically attenuated super-antigen toxin vaccines altered such that superantigen attributes are absent, however the superantigen is effectively recognized and an appropriate immune response is produced. The attenuated superantigen toxins are shown to protect animals against challenge with wild type toxin. Methods of producing and using the altered superantigen toxins are described.

Luz D. Ortiz,

Army Federal Register Liaison Officer.